Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies

Buffin, Sophie; Peubez, Isabelle; Barriere, Fabienne; Nicolaı̈, Marie-Claire; Tapia, Tenekua; Dhir, Vipra; Forma, Eric; Sève, Nicolas; Legastelois, Isabelle

doi:10.1016/j.vaccine.2019.09.057

Cited by 24 publications

(28 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The construction of VLPs was conducted as described in the previous study [ 11 ]. VLPs were based on a recombinant Baculovirus (rBV) expressing system using the HPAI H5N1 virus (A/chicken/Egypt/121/2012) [ 15 ].…”

Section: Methodsmentioning

confidence: 99%

“…Commercialized prophylactic VLPs-based vaccines have been developed, including baculovirus-derived papillomavirus VLPs vaccines against cervical cancer and hepatitis B virus VLPs vaccines against chronic hepatitis B virus infection [ 8 , 9 ], which support the development of additional baculovirus-derived vaccines. Influenza VLPs are a new generation of egg-independent candidate vaccines that encode genes for the three influenza virus proteins, hemagglutinin (HA) and neuraminidase (NA), along with the viral core protein matrix (M1) [ 10 , 11 ]. However, the application of VLP-based vaccines against AIVs is still under optimization.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

El-Husseiny¹,

Hagag²,

Pushko

et al. 2021

Vaccines

View full text Add to dashboard Cite

Highly pathogenic Avian Influenza (HPAI) viruses continue to cause severe economic losses in poultry species worldwide. HPAI virus of subtype H5N1 was reported in Egypt in 2006, and despite vaccination efforts, the virus has become endemic. The current study aims to evaluate the efficacy of a virus-like particle (VLP) based vaccine in vivo using specific pathogen-free (SPF) chickens. The vaccine was prepared from the HPAI H5N1 virus of clade 2.2.1.2 using the baculovirus expression system. The VLPs were quantitated and characterized, including electron microscopy. In addition, the protection level of the VLPs was evaluated by using two different regimens, including one dose and two-dose vaccinated groups, which gave up to 70% and 100% protection level, respectively. The results of this study emphasize the potential usefulness of the VLPs-based vaccine as an alternative vaccine candidate for the control of AIV infection in poultry.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

El-Husseiny¹,

Hagag²,

Pushko

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…[61] It has been suggested that using multistructural VLPs as vaccines, instead of the classic influenza vaccine method using embryonated chicken eggs, could produce immune responses that would defend against the different forms of influenza. [34,60,62,63] More investigation is necessary, but influenza VLPs have the potential to save time and labor spent continuously developing subtype-and strain-specific influenza vaccines. Even as VLPs are used to address challenges that plagued for centuries, they are also being considered as novel infectious diseases emerge.…”

Section: Virus-like Particles For Infectious Diseasesmentioning

confidence: 99%

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Lutz

Popowski

Dinh

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVID‐19). The different vaccine types investigated for the prevention of COVID‐19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno‐associated viruses, virus‐like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID‐19 in terms of vaccines and therapeutics.

show abstract

“…To assemble into VLPs M1 must interact with proteins containing a cytoplasmic tail region such as HA (hemagglutinin) and NA (neuraminidase) 56 . M1 VLPs have been made with different combinations of influenza surface glycoproteins or envelope proteins from other viruses and has been expressed in mammalian and insect systems 57 , 58 . M1 VLPs were used in a SARS-CoV vaccine, consisting of M1 envelope protein and chimeric spike protein 19 .…”

Section: Introductionmentioning

confidence: 99%

Protein-based antigen presentation platforms for nanoparticle vaccines

2021

View full text Add to dashboard Cite

Modern vaccine design has sought a minimalization approach, moving to the isolation of antigens from pathogens that invoke a strong neutralizing immune response. This approach has created safer vaccines but may limit vaccine efficacy due to poor immunogenicity. To combat global diseases such as COVID-19, malaria, and AIDS there is a clear urgency for more effective next-generation vaccines. One approach to improve the immunogenicity of vaccines is the use of nanoparticle platforms that present a repetitive array of antigen on its surface. This technology has been shown to improve antigen presenting cell uptake, lymph node trafficking, and B-cell activation through increased avidity and particle size. With a focus on design, we summarize natural platforms, methods of antigen attachment, and advancements in generating self-assembly that have led to new engineered platforms. We further examine critical parameters that will direct the usage and development of more effective platforms.

show abstract

Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies

Cited by 24 publications

References 47 publications

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Protein-based antigen presentation platforms for nanoparticle vaccines

Contact Info

Product

Resources

About